Growth Metrics

Merck (MRK) Non-Current Deferred Tax Liability (2016 - 2026)

Merck has reported Non-Current Deferred Tax Liability over the past 18 years, most recently at $1.5 billion for Q1 2026.

  • Quarterly Non-Current Deferred Tax Liability rose 6.03% to $1.5 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Mar 2026, up 6.03% year-over-year, with the annual reading at $1.4 billion for FY2025, 52.91% down from the prior year.
  • Non-Current Deferred Tax Liability was $1.5 billion for Q1 2026 at Merck, up from $1.4 billion in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $3.1 billion in Q1 2022 and troughed at $864.0 million in Q3 2024.
  • The 5-year median for Non-Current Deferred Tax Liability is $1.4 billion (2025), against an average of $1.7 billion.
  • Year-over-year, Non-Current Deferred Tax Liability soared 155.07% in 2022 and then crashed 66.51% in 2023.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $1.8 billion in 2022, then skyrocketed by 64.79% to $3.0 billion in 2023, then increased by 3.31% to $3.1 billion in 2024, then plummeted by 52.91% to $1.4 billion in 2025, then rose by 3.82% to $1.5 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Non-Current Deferred Tax Liability are $1.5 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025).